Abstract:Background & Aims: Programmed death-ligand 1 (PD-L1) has been recognized as a critical and promising target in therapies that direct immune escape of cancers. However, its association with aggressive clinicopathological features in solid tumors remains unclear. We investigated this question by synthesizing published articles.Methods: Electronic databases were searched for relevant studies. Outcomes of interest included age, gender, tumor size, tumor size, lymph node metastasis and tumor cell differentiation.Results: A total of 61 studies involving 17 types of malignancies were included. The overall expression rate of PD-L1 was 44.5% (95% CI, 37.5% to 51.6 %). Patients with regional lymph node metastases (OR 1.38; P < 0.01), large size tumor (OR 1.89; P < 0.01) or poor differentiated tumors (OR 1.71; P < 0.01) were associated with higher PD-L1 expression rate. However, no significant association was observed between young and elder patients (OR 1.04; P = 0.58), or male and female patients (OR 1.13; P = 0.06). A numerically higher PD-L1 expression rate was detected in polyclonal antibodies (57.2%) than monoclonal antibodies (39.6%). In addition, the PD-L1 expression rate reported by studies from Asian areas (52.3%) was numerically higher than those from non-Asian areas, namely Caucasians (32.7%).Conclusions: This meta-analysis indicated that patients with larger tumors, regional lymph node metastases, or poor-differentiated tumors were associated with a higher PD-L1 expression rate; in addition the expression rate of PD-L1 in Asians might be higher than that of Caucasians. This information might be useful in screening candidates for relevant tests and treatments.

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

Recent Findings in the Posttranslational Modifications of PD-L1

PD-1 regulation in immune homeostasis and immunotherapy

Programmed cell death-ligand 2: new insights in cancer

Programmed Death 1/programmed Death Ligand 1 Signaling Pathway in Tumor Immunotherapy: an Update

Regulation of PD-L1 expression in the tumor microenvironment

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Research progress in the regulation of programmed cell death 1 receptor and its ligand pathway and the strategies against tumor drug resistance

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

[Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review]

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

PD-1/PD-Ls SignaI Pathway and the Appiication of Anti-Pd-1/pd-ls Antibodies in Cancer Therapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Recent Advances In The Development Of Pd-L1 Modulators: Degraders, Downregulators, And Covalent Inhibitors

Generation, secretion and degradation of cancer immunotherapy target PD-L1

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

The Prevalence and Clinicopathological Features of Programmed Death-Ligand 1 (PD-L1) Expression: a Pooled Analysis of Literatures

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1